在免疫治疗期间,表观遗传调节器控制克隆造血细胞的CD8T干细胞
Tae Gun Kang1, Xin Lan1,2, Tian Mi1
1Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
概括
在癌症免疫治疗中,像ASXL1这样的表观遗传调节剂对T细胞耗尽至关重要. 调节这些表观遗传因素可以增强抗瘤免疫力,改善患者的生存率.
科学领域:
- 免疫学
- 表观遗传学
- 癌症研究
背景情况:
- 在癌症免疫治疗中,T细胞耗尽是关键障碍,限制了T细胞反应的有效性.
- 在慢性抗原暴露和抗瘤免疫期间控制T细胞耗尽的特定表观遗传调节剂仍然不完全理解.
研究的目的:
- 研究三种常见突变表观遗传调节剂 (Dnmt3a,Tet2,Asxl1) 在T细胞干细胞和对检查点阻断免疫疗法的反应中的作用.
- 阐明这些调节剂影响T细胞功能和抗瘤免疫力的机制.
主要方法:
- 在慢性抗原暴露期间分析缺少Dnmt3a,Tet2或Asxl1的CD8T细胞.
- 通过H2AK119无处不在和表观遗传途径对Asxl1在T细胞自我更新和分化中的作用的研究.
- 在实验模型中评估与抗PD-L1免疫疗法的Asxl1缺乏T细胞.
主要成果:
- 缺少Dnmt3a,Tet2或Asxl1的CD8T细胞在没有恶性转变的情况下维持了一年多的原始细胞 (Tpex) 群体.
- Asxl1 缺乏保留了T细胞的自我更新能力,并降低了CD8 T细胞的分化.
- 在临床前模型中,缺乏Asxl1的T细胞与抗PD- L1免疫疗法产生了协同作用,从而改善瘤控制和提高存活率.
结论:
- 通过特定的表观遗传机制,Asxl1在调节T细胞耗尽和抗瘤免疫力方面发挥着关键作用.
- 针对像Asxl1这样的表观遗传调节剂有望提高癌症免疫疗法的有效性.
- 缺乏Asxl1的T细胞可能是改善患者癌症治疗结果的有价值的治疗策略.
相关概念视频
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Multipotency of Hematopoietic Stem Cells
3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Lineage Commitment
3.0K
Commitment is the process whereby stem cells:
3.0K
T Cell Activation and Clonal Selection
679
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
679
Role of Hematopoietic Growth Factors
1.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.3K
Cancer Stem Cells and Tumor Maintenance
4.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K


